» Articles » PMID: 7512467

Individualised Selection of Antihypertensive Therapy

Overview
Journal Drugs
Specialty Pharmacology
Date 1993 Jan 1
PMID 7512467
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Theoretically, it should be possible to match the requirements of individual patients with the pharmacological and clinical properties of the large number of antihypertensive drugs now available. The concept of automatic sequential stepped-care therapy is now largely outdated, but therapy of clinically important hypertension must be initiated with one agent. Diuretics remain a first-line option in the elderly and in Black patients, as do calcium antagonists. Outcome trials are available only for the elderly, and in these the benefits of initial diuretic therapy are well documented. Nonetheless, diuretics may often need to be co-prescribed with a beta-blocker or an adrenergic modifier such as methyldopa. beta-Blockers are preferred in patients with ischaemic heart disease or enhanced adrenergic drive, while alpha-blockers are preferred in patients with blood lipid abnormalities or prostatic problems. Calcium antagonists or angiotensin converting enzyme (ACE) inhibitors are being increasingly used as initial therapy when quality of life is important and metabolic neutrality is required. Calcium antagonists are more likely to be effective first-line therapy than ACE inhibitors in patients with a high salt intake, in patients with Raynaud's disease, when angina pectoris is present, and in Black patients. ACE inhibitors are preferred for combination with diuretic agents, and in the presence of congestive heart failure or low salt intake. Experimentally, both calcium antagonists and ACE inhibitors can prevent ischaemic ventricular fibrillation and atheroma. Combination therapy between these 2 drug classes is gaining increasing acceptance because of these theoretical advantages.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Effects of verapamil slow release plus trandolapril combination therapy on essential hypertension.

Derici U, Sindel S, Arinsoy T, Bali M, Goker B, Cemri M Curr Ther Res Clin Exp. 2014; 64(1):10-20.

PMID: 24944353 PMC: 4053024. DOI: 10.1016/S0011-393X(03)00007-9.


Clinical pharmacokinetics of vasodilators. Part I.

Kirsten R, Nelson K, Kirsten D, Heintz B Clin Pharmacokinet. 1998; 34(6):457-82.

PMID: 9646008 DOI: 10.2165/00003088-199834060-00003.

References
1.
Opie L, Coetzee W, Dennis S, Thandroyen F . A potential role of calcium ions in early ischemic and reperfusion arrhythmias. Ann N Y Acad Sci. 1988; 522:464-77. DOI: 10.1111/j.1749-6632.1988.tb33386.x. View

2.
Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G . Primary prevention with metoprolol in patients with hypertension. Mortality results from the MAPHY study. JAMA. 1988; 259(13):1976-82. View

3.
Zanchetti A . Role of calcium antagonists in systemic hypertension. Am J Cardiol. 1987; 59(3):130B-136B. DOI: 10.1016/0002-9149(87)90092-0. View

4.
Jee L, Opie L . Acute hypotensive response to nifedipine added to prazosin in treatment of hypertension. Br Med J (Clin Res Ed). 1983; 287(6404):1514. PMC: 1549987. DOI: 10.1136/bmj.287.6404.1514. View

5.
Sheu W, Swislocki A, Hoffman B, Chen Y, Reaven G . Comparison of the effects of atenolol and nifedipine on glucose, insulin, and lipid metabolism in patients with hypertension. Am J Hypertens. 1991; 4(3 Pt 1):199-205. DOI: 10.1093/ajh/4.3.199. View